Progesterone Receptor Positive (PR+) breast cancer is a distinct biological subtype of hormone receptor positive breast cancer. This type of cancer grows in response to progesterone, a hormone that is ...
An interview with Dr. Kimberly Allison from Stanford University School of Medicine and Dr. Antonio Wolff from Johns Hopkins University on "Estrogen and Progesterone Receptor Testing in Breast Cancer ...
MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.
In a recent study published in the journal JAMA Network Open, researchers evaluated the incidence of breast cancer among young women between the ages of 20 and 49 years. They assessed the incidence ...
Prognostic profiling of hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors beyond progression (BP): A synthetic control arm biomarker ...
Until recently, most women who underwent adjuvant hormone therapy to reduce the chance of a breast cancer recurrence took tamoxifen every day for 5 years. However, with the advent of newer hormone ...
Migraines are throbbing headaches often accompanied by nausea and increased sensitivity to light, sound and touch. Nearly 30 million Americans suffer from migraines, and almost 1 in 4 of them have at ...
Once again I am extremely lucky to have this article co-written by a senior graduate student who's an expert on how reproductive hormones act on the brain. Stephanie Koebele is completing her Ph.D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results